Bruker's (BRKR) Bruker Microbiology & Infection Diagnostics division said Friday it has rolled out molecular diagnostics system MyGenius PRO in Europe.
The new diagnostics system is based on polymerase chain reaction, developed to diagnose infectious diseases, according to the division.
Bruker Microbiology said the MyGenius PRO system automates the complete workflow from patient sample to diagnostic result, adding it developed the system in partnership with ELITechGroup and Hitachi High Tech-Corp.
Additionally, Hitachi will launch the platform in Japan under the LABOSPECT GA-5 trade name, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments